Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003243 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003243: Completed Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00003243 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003243, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. White blood cells from donors may be able to kill cancer cells in patients who have hematologic cancer that has recurred following bone marrow transplantation. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus infusion of donated white blood cells in treating patients who have hematologic cancer that has recurred after bone marrow transplantation.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL aldesleukin
- BIOLOGICAL filgrastim
- BIOLOGICAL therapeutic allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-01 |
| Phase | Phase 1 |
What the finished NCT00003243 record still lists
NCT00003243 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003243 about?
NCT00003243 is a clinical study titled "Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. White blood cells from donors may be able to kill cancer cells in patients who have hematologic cancer that has recurred f...
What is the current status of trial NCT00003243?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-01.
What interventions are being tested in trial NCT00003243?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), aldesleukin (BIOLOGICAL), filgrastim (BIOLOGICAL), therapeutic allogeneic lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003243?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia